AB Science (EUR)
AB
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 6.63 | 7.29 |
| 52-Wk Range | | |
| Last Close | 6.94 |
| Mkt Cap (m) | 295.11 |
| Dividend yield | - |
| ISIN | FR0010557264 |
| Volume | 218,521 |
| Exchange Venue | PAR |
Company Profile
AB Science is a pharmaceutical company. It is engaged in research, development, & commercialization of tyrosine kinase inhibitors, therapeutic drugs used in treating cancerous tumors, inflammatory & neuro-degenerative diseases in both humans & animals.
Key Information
| Price/Earning | - |
| Price/Book | 0.00 |
| Price/Sales | 161.91 |
| P/CF | - |
| Rev Growth (3 year avg) | - |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | - |
| Debt/Equity | - |
Documents
Financials
Income Statement
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Revenue (m) | 2 | 2 | 2 | 2 | 2 | - |
| Operating Income (m) | -15 | -26 | -30 | -28 | -29 | - |
| Net Income (m) | -16 | -27 | -28 | -27 | -26 | - |
| Basic EPS | -0.49 | -0.78 | -0.78 | -0.75 | -0.69 | - |
| Avg. Diluted Shares Outstanding (m) | 33 | 34 | 36 | 36 | 38 | - |
Balance Sheet
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Current Assets (m) | 30 | 31 | 36 | 49 | 21 | - |
| Non Current Assets (m) | 2 | 2 | 2 | 2 | 2 | - |
| Total Assets (m) | 31 | 33 | 38 | 51 | 22 | - |
| Current Liabilities (m) | 14 | 18 | 20 | 19 | 19 | - |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | -16 | -17 | -5 | 11 | -15 | - |
Cash Flows
| EUR | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Operating Cash Flows (m) | -14 | -23 | -34 | -23 | -27 | - |
| Capital Expenditure (m) | -1 | -1 | -1 | -1 | - |
Figures are quoted in EUR unless stated otherwise
-
No change
€
6.94
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.